Skip to main content

Affymetrix Shares Down 9 Percent After Warning of Slowdown in 500K Array Market

NEW YORK, Feb. 28 (GenomeWeb News) - Affymetrix shares were down 9.1 percent,or $3.58, at $35.77 in afternoon trade amid general weakness in drug stocks and following an SEC filing in which the company said that "the market for whole genome mapping products has temporarily slowed."

 

In the filing, Affymetrix announced the opening of a new probe array manufacturing facility in Singapore. It also reported that recent production yields on its Mapping 500K array set "consistently exceed 75 percent" in its Sacramento,Calif., facility and that it expected to meet customer demand for the product in 2006.

 

However, the company noted that "since many customers complete projects before reordering, this may affect the timing of the 500K product reorders" and that these "factors ... may increase the risk around our expected revenue targets for the Mapping 500K Array Set."

 

Affymetrix did not announce a revenue target for the 500K, and has not in the past.

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.